Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. We describe a case report of a patient with spindle cell sarcoma who developed severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon stopping therapy.
Keywords: cardio-oncology; cardiomyopathy; cardiotoxicity; oncology; pazopanib; tyrosine kinase inhibitors; vascular-endothelial growth factor.